Exercise effects on adipokines and the IGF axis in men with prostate cancer treated with androgen deprivation: A randomized study

Journal of the Canadian Urological Association

Volumn 7, Issue 11-12, 2013, Pages

  Santa Mina, Daniel ^b,c   Connor, Michael K ^b   Alibhai, Shabbir M H ^d,e   Toren, Paul ^d   Guglietti, Crissa ^b   Matthew, Andrew G ^a   Trachtenberg, John ^a   Ritvo, Paul ^b,f  

^a PRINCESS MARGARET HOSPITAL   (Canada)

^b YORK UNIVERSITY   (Canada)

^c UNIVERSITY OF GUELPH   (Canada)

^d UNIVERSITY OF TORONTO   (Canada)

^e TORONTO GENERAL HOSPITAL   (Canada)

^f CANCER CARE ONTARIO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84887335163     PISSN: 19116470     EISSN: None     Source Type: Journal    
DOI: 10.5489/cuaj.235     Document Type: Article

References (40)

1. Alibhai SM, Gogov S, Allibhai Z. Long-term side effects of androgen deprivation therapy in men with non-metastatic prostate cancer: a systematic literature review. Crit Rev Oncol Hematol 2006;60:201-15. http://dx.doi.org/10.1016/j.critrevonc.2006.06.006
2. Galvao DA, Spry NA, Taaffe DR, et al. Changes in muscle, fat and bone mass after 36 weeks of maximal androgen blockade for prostate cancer. BJU Int 2008;102:44-73. http://dx.doi.org/10.1111/j.1464-410X.2008.07539.x
3. Shahinian VB, Yong-Fang K, Freeman JL, et al. Risk of fracture after androgen deprivation for prostate cancer. New Engl J Med 2005;352:154-64. http://dx.doi.org/10.1056/NEJMoa041943
4. Ornish D, Weidner G, Fair WR, et al. Intensive lifestyle changes may affect the progression of prostate cancer. J Urol 2005;174:1065-70. http://dx.doi.org/10.1097/01.ju.0000169487.49018.73
5. Shaneyfelt T, Husein R, Bubley G, et al. Hormonal predictors of prostate cancer: a meta-analysis. J Clin Oncol 2000;18:847-53.
6. Kelesidis I, Kelesidis T, Mantzoros CS. Adiponectin and cancer: a systematic review. Br J Cancer 2006;94:1221-5. http://dx.doi.org/10.1038/sj.bjc.6603051
7. Garofalo C, Surmacz E. Leptin and cancer. J Cell Phys 2006;207:12-22. http://dx.doi.org/10.1002/ jcp.20472
8. Dalamaga M, Diakopoulos KN, Mantzoros CS. The Role of Adiponectin in Cancer: A Review of Current Evidence. Endocr Rev 2012;33:547-94. http://dx.doi.org/10.1210/er.2011-1015
9. Smith MR, Finkelstein JS, McGovern FJ, et al. Changes in body composition during androgen deprivation therapy for prostate cancer. J Clin Endocrinol Metab 2002;87:599-603. http://dx.doi.org/10.1210/ jc.87.2.599
10. Santa Mina D, Alibhai SMH, Matthew AG, et al. A Randomized Trial of Aerobic versus Resistance Exercise in Prostate Cancer Survivors. J Aging Phys Act 2012; 2013 Oct;21(4):455-78. Epub 2012 Dec 10.
11. Heyward VH. Advanced fitness assessment and exercise prescription. Windsor, Ontario: Human Kinetics; 2010.
12. Lerman J, Bruce RA, Sivarajan E, et al. Low level dynamic exercises for earlier cardiac rehabilitation: Aerobic and hemodynamic responses. Arch Phys Med Rehabil 1976;57:355-60.
13. American College of Sports Medicine. ACSM's guidelines for exercise testing and prescription. New York: Lippincott Williams and Wilkins; 2005.
14. Godin G, Shephard RJ. A simple method to assess exercise behaviour in the community. Can J App Sport Sci 1985;10:141-6.
15. Westerlind KC. Physical activity and cancer prevention: Mechanisms. Med Sci Sports Exerc 2003;35:1834-40. http://dx.doi.org/10.1249/01.MSS.0000093619.37805.B7
16. Chan JM, Stampfer MJ, Giovannucci E, et al. Plasma insulin-like growth factor-I and prostate cancer risk: a prospective study. Science 1998;279:563-6. http://dx.doi.org/10.1126/science.279.5350.563
17. Wolk A, Mantzoros CS, Andersson SO, et al. Insulin-like growth factor 1 and prostate cancer risk: a population-based, case-control study. J Natl Cancer Inst 1998;90:911-15. http://dx.doi.org/10.1093/ jnci/90.12.911
18. Bourke L, Doll H, Crank H, et al. Lifestyle intervention in men with advanced prostate cancer receiving androgen suppression therapy: a feasibility study. Cancer Epidemiol Biomarkers Prev 2011;20:647-57. http://dx.doi.org/10.1158/1055-9965.EPI-10-1143
19. Liu Y, Hu F, Li D, et al. Does physical activity reduce the risk of prostate cancer? A systematic review and meta-analysis. Euro Urol 2011;60:1029-44. http://dx.doi.org/10.1016/j.eururo.2011.07.007
20. Kenfield SA, Stampfer MJ, Giovannucci E, et al. Physical activity and survival after prostate cancer diagnosis in the Health Professionals Follow-Up Study. J Clin Oncol 2011;29:726-32. http://dx.doi. org/10.1200/JCO.2010.31.5226
21. Goktas S, Yilmaz MI, Caglar K, et al. Prostate cancer and adiponectin. Urol 2005;65:1168-72. http:// dx.doi.org/10.1016/j.urology.2004.12.053
22. Michalakis K, Williams CJ, Mitsiades N, et al. Serum adiponectin concentrations and tissue expression of adiponectin receptors are reduced in patients with prostate cancer: a case control study. Cancer Epidemiol Biomarkers Prev 2007;16:308-13. http://dx.doi.org/10.1158/1055-9965.EPI-06-0621
23. Mistry T, Digby JE, Desai KM, et al. Obesity and prostate cancer: a role for adipokines. Eur Urol 2007;52:46-53. http://dx.doi.org/10.1016/j.eururo.2007.03.054
24. Somasundar P, Frankenberry KA, Skinner H, et al. Prostate cancer cell proliferation is influenced by leptin1. J Surg Res 2004;118:71-82. http://dx.doi.org/10.1016/j.jss.2004.01.017
25. Saglam K, Aydur E, Yilmaz M, et al. Leptin influences cellular differentiation and progression in prostate cancer. J Urol 2003;169:1308-11. http://dx.doi.org/10.1097/01.ju.0000055903.18400.25
26. O'Leary VB, Marchetti CM, Krishnan RK, et al. Exercise-induced reversal of insulin resistance in obese elderly is associated with reduced visceral fat. J Appl Physiol 2006;100:1584-9. http://dx.doi.org/10.1152/ japplphysiol.01336.2005
27. Fatouros IG, Tournis S, Leontsini D, et al. Leptin and adiponectin responses in overweight inactive elderly following resistance training and detraining are intensity related. J Clin Endocrinol Metabol 2005;90:5970-8. http://dx.doi.org/10.1210/jc.2005-0261
28. Furlanetto RW, Harwell SE, Frick KK. Insulin-like growth factor-I induces cyclin-D1 expression in MG63 human osteosarcoma cells in vitro. Mol Endocrinol 1994;8:510-7. http://dx.doi.org/10.1210/me.8.4.510
29. Parrizas M, LeRoith D. Insulin-like growth factor-1 inhibition of apoptosis is associated with increased expression of the bcl-xL gene product. Endocrinol 1997;138:1355-8. http://dx.doi.org/10.1210/ en.138.3.1355
30. Leung PS, Aronson WJ, Ngo TH, et al. Exercise alters the IGF axis in vivo and increases p53 protein in prostate tumor cells in vitro. J Appl Physiol 2004;96:450-4. http://dx.doi.org/10.1152/japplphysiol. 00871.2003
31. Akagi Y, Liu W, Zebrowski B, et al. Regulation of vascular endothelial growth factor expression in human colon cancer by insulin-like growth factor-I. Cancer Res 1998;58:4008-14.
32. Fukuda R, Hirota K, Fan F, et al. Insulin-like growth factor 1 induces hypoxia-inducible factor 1-mediated vascular endothelial growth factor expression, which is dependent on MAP kinase and phosphatidylinositol 3-kinase signaling in colon cancer cells. J Biol Chem 2002;277:38205-11. http://dx.doi.org/10.1074/ jbc.M203781200
33. Stattin P, Rinaldi S, Biessy C, et al. High levels of circulating insulin-like growth factor-I increase prostate cancer risk: a prospective study in a population-based nonscreened cohort. J Clin Oncol 2004;22:3104-12. http://dx.doi.org/10.1200/JCO.2004.10.105
34. Lopez JB, Sahabudin RM, Chin LP. Are plasma insulin-like growth factor I (IGF-I) and IGF-binding protein 3 (IGFBP-3) useful markers of prostate cancer? Int J Biol Markers 2004;19:164-7.
35. Miyata Y, Sakai H, Kanda S, et al. Expression of insulin-like growth factor binding protein-3 before and after neoadjuvant hormonal therapy in human prostate cancer tissues: correlation with histopathologic effects and biochemical recurrence. Urol 2004;63:1184-90. http://dx.doi.org/10.1016/j.urology.2004.02.015
36. Djavan B, Waldert M, Seitz C, et al. Insulin-like growth factors and prostate cancer. World J Urol 2001;19:225-33.
37. Russell PJ, Bennett S, Stricker P. Growth factor involvement in progression of prostate cancer. Clin Chem 1998;44:705-23.
38. Ngo TH, Barnard RJ, Tymchuk CN, et al. Effect of diet and exercise on serum insulin, IFG-I, and IFGBP-1 levels and growth of LNCaP cells in vitro. Cancer Causes Control 2002;13:929-35. http://dx.doi. org/10.1023/A:1021911517010
39. Barnard RJ, Ngo TH, Leung PS, et al. A low-fat diet and/or strenuous exercise alters the IGF axis in vivo and reduces prostate tumor cell growth in vitro. Prostate 2003;56:201-6. http://dx.doi.org/10.1002/ pros.10251
40. Fairey AS, Courneya KS, Field CJ, et al. Effects of exercise training on fasting insulin, insulin resistance, insulin-like growth factors, and insulin-like growth factor binding proteins in postmenopausal breast cancer survivors: a randomized controlled trial. Cancer Epidemiol Biomarkers Prev 2003;12:721-7.